EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

Clinical phenotypes and renal outcomes in PLA2R-associated membranous nephropathy: a multi-center cohort study with unsupervised cluster analysis

Jing Miao iD, Jaleh Zand, Lisa Vaughan, Maria Jose Soler iD, Montserrat M Díaz Encarnación, Luis F Quintana iD, Andrew S Bomback, Charat Thongprayoon, Benjamin Wooden, Shane A Bobart iD, Wisit Cheungpasitporn, Fernando C Fervenza iD und 1 weitere

Nephrology Dialysis Transplantation · 2025

DOI: 10.1093/ndt/gfaf107 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Nephrology Dialysis Transplantation, 2025. Verfasst von Jing Miao und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN, USA. Hauptthemen laut MEDLINE: Glomerulonephritis, Membranous, Receptors, Phospholipase A2, Kidney Failure, Chronic, Autoantibodies. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Membranous nephropathy (MN) associated with phospholipase A2 receptor (PLA2R) antibodies is the most common cause of nephrotic syndrome in non-diabetic adult patients. This study investigated the relationship between clinical phenotypes and renal outcomes in this population, emphasizing the potential for phenotype-based treatment stratification.

Methods

We conducted a retrospective, multi-center cohort study of PLA2R-positive MN. Unsupervised cluster analysis grouped patients based on clinicopathological characteristics. Primary outcomes included complete or partial remission within 2 years of biopsy and end-stage kidney disease (ESKD) or death during follow-up.

Results

Among 178 patients, three distinct clusters emerged (n = 89, 70, and 19). Within 2 years of biopsy, 102 patients (57%) achieved complete or partial remission. Cluster 1, characterized by the mildest disease markers, including the lowest body mass index, serum anti-PLA2R titer, serum creatinine, proteinuria, and triglycerides, had the highest remission rate of 72%, compared with 50% in cluster 2 and 54% in cluster 3. Cluster 2 had significantly lower remission compared to cluster 1 (HR 0.64, 95% CI 0.42–0.96, P = .03); results were similar in cluster 3, albeit not statistically significant (HR 0.50, 95% CI 0.23–1.09, P = .08). Elevated anti-PLA2R levels (>100 U/ml) and proteinuria (>8 g/24-hour) predicted reduced remission (HR 0.56, 95% CI 0.36–0.88, P = .01; HR 0.43, 95% CI 0.26–0.73, P = .002, respectively), while high high-density lipoprotein levels were protective (HR 1.01, 95% CI 1.00–1.02, P = .048). Overall, 21 patients (12%) developed ESKD or died. ESKD-free survival differed significantly across clusters (log-rank test P = .04).

Conclusions

Unsupervised clustering identified distinct clinical phenotypes in PLA2R-positive MN, each associated with different renal prognoses. Phenotype-based risk stratification could enhance treatment precision, improve patient outcomes, and potentially reduce treatment-related adverse effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, MembranousReceptors, Phospholipase A2Kidney Failure, ChronicAutoantibodiesHumansMaleFemaleRetrospective StudiesMiddle AgedPhenotypePrognosisCluster AnalysisAdultFollow-Up StudiesGlomerular Filtration RateAgedBiomarkers

Stichwörter der Autor:innen

PLA2R-associated nephropathyclinical phenotypingmembranous nephropathyrenal prognosisunsupervised clustering

Substanzen

Receptors, Phospholipase A2PLA2R1 protein, humanAutoantibodiesBiomarkers

Autor:innen und Institutionen

  • Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
  • Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.
  • CSUR Enfermedad Glomerular Compleja, Nephrology and Transplantation Research Group, Vall d'Hebron Institut de Recerca, Vall d'Hebron Hospital Universitari, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • CSUR: Spain Reference Center for Complex Glomerular Diseases, ERKnet: European Reference Center for Rare Kidney Diseases. Fundació Puigvert Department of Nephrology, Universitat Autonoma de Barcelona, Barcelona, Spain.
  • CSUR Enfermedad Glomerular Compleja, Servicio de Nefrología y Trasplante Renal, Hospital Clínic de Barcelona, Universtat de Barcelona, IDIBAPS, Barcelona, Spain.
  • Department of Medicine, Division of Nephrology, Vagelos College of Physicians & Surgeons, Columbia University, New York, NY, USA.

ORCID-Profile: Jing Miao, Maria Jose Soler, Luis F Quintana, Shane A Bobart, Fernando C Fervenza

Zitieren

APA

Miao, J., Zand, J., Vaughan, L., Soler, M. J., Díaz Encarnación, M. M., Quintana, L. F., Bomback, A. S., Thongprayoon, C., Wooden, B., Bobart, S. A., Cheungpasitporn, W., Fervenza, F. C., & Zand, L. (2025). Clinical phenotypes and renal outcomes in PLA2R-associated membranous nephropathy: a multi-center cohort study with unsupervised cluster analysis. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfaf107

Vancouver

Miao J, Zand J, Vaughan L, Soler MJ, Díaz Encarnación MM, Quintana LF, et al. Clinical phenotypes and renal outcomes in PLA2R-associated membranous nephropathy: a multi-center cohort study with unsupervised cluster analysis. Nephrology Dialysis Transplantation. 2025. doi:10.1093/ndt/gfaf107

BibTeX
@article{Miao2025,
  author = {Miao, Jing and Zand, Jaleh and Vaughan, Lisa and Soler, Maria Jose and Díaz Encarnación, Montserrat M and Quintana, Luis F and Bomback, Andrew S and Thongprayoon, Charat and Wooden, Benjamin and Bobart, Shane A and Cheungpasitporn, Wisit and Fervenza, Fernando C and Zand, Ladan},
  title = {Clinical phenotypes and renal outcomes in PLA2R-associated membranous nephropathy: a multi-center cohort study with unsupervised cluster analysis},
  journal = {Nephrology Dialysis Transplantation},
  year = {2025},
  doi = {10.1093/ndt/gfaf107}
}
Kostenlos starten →